Læknablaðið - 15.01.1999, Qupperneq 36

32
LÆKNABLAÐIÐ 1999; 85
13. Drueke TB. The pathogenesis of parathyroid gland hyper-
plasia in chronic renal failure. Kidney Int 1995; 48: 259-72.
14. Tominaga Y, Kohara S, Namii Y, Nagasaka T, Haba T,
Uchida K, et al. Clonal analysis of nodular parathyroid
hyperplasia in renal hyperparathyroidism. World J Surg
1996; 20: 744-50.
15. Arnold A, Brown MF, Urena P, Gaz RD, Sarfati E, Drueke
TB. Monoclonality of parathyroid tumors in chronic renal
failure and in primary parathyroid hyperplasia. J Clin Invest
1995;95:2047-53.
16. Falchetti A, Bale AE, Amorosi A, Bordi C, Cicchi P.
Bandini S, et al. Progression of uremic hyperparathyroi-
dism involves allelic loss on chromosome 11. J Clin Endo-
crinol Metab 1993; 76: 139-44.
17. Diethelm AG, Adams PL, Murad TM, Daniel WW,
Whelchel JD, Rutsky EA, et al. Treatment of secondary
hyperparathyroidism in patients with chronic renal failure
by total parathyroidectomy and parathyroid autograft. Ann
Surg 1981; 193:777-93.
18. Korkor AB. Reduced binding of [3H]l,25-dihydroxyvita-
min D3 in the parathyroid glands of patients with renal fai-
lure. NEJM 1987; 316: 1573-7.
19. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa
K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor
density is associated with a more severe form of parathy-
roid hyperplasia in chronic uremic patients. J Clin Invest
1993; 92: 1436-43.
20. Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda
SA, Bartholomay D,et al. Prospective trial of pulse oral ver-
sus intravenous calcitriol treatment of hyperparathyroidism
in ESRD. Kidney Int 1994; 45: 1710-21.
21. Parfitt AM. Hypercalcemic hyperparathyroidism following
renal transplantation: differential diagnosis, management,
and implications for cell population control in the para-
thyroid gland. Miner Electrolyte Metab 1982; 8: 92-112.
22. McCarron DA, Muther RS, Lenfesty B, Bennett WM. Para-
thyroid function in persistent hyperparathyroidism: rela-
tionship to gland size. Kidney Int 1982; 22: 662-70.
23. Gittes RF, Radde IC. Experimental model for hyperpara-
thyroidism: effect of excessive numbers of transplanted iso-
logous parathyroid glands. J Urol 1966; 95: 595-603.
24. Mayer GP, Habener JF, Potts JT, Jr. Parathyroid hormone
secretion in vivo. Demonstration of a calcium-independent
nonsuppressible component of secretion. J Clin Invest
1976; 57:678-83.
25. Goodman WG, Belin TR, Salusky IB. In vivo assessments
of calcium-regulated parathyroid hormone release in secon-
dary hyperparathyroidism. Kidney Int 1996; 50: 1834-44.
26. Khosla S, Ebeling PR, Firek AF, Burritt MM, Kao PC,
Heath H. Calcium infusion suggests a „set-point“ abnorma-
lity of parathyroid gland function in familial benign hyper-
calcemia and more complex disturbances in primary hyper-
parathyroidism. J Clin Endocrinol Metab 1993; 76: 715-20.
27. Pollak MR, Brown EM, Chou YH, Hebert SC, Marx SJ,
Steinmann B, et al. Mutations in the human Ca(2+)-sensing
receptor gene cause familial hypocalciuric hypercalcemia
and neonatal severe hyperparathyroidism. Cell 1993; 75:
1297-303.
28. Indridason OS, Heath H, Khosla S, Yohay DA, Quarles LD.
Non-suppressible parathyroid hormone secretion is related
to gland size in uremic secondary hyperparathyroidism.
Kidney Int 1996; 50: 1663-71.
29. Ramirez JA, Goodman WG, Gornbein J, Menezes C,
Moulton L, Segre GV, et al. Direct in vivo comparison of
calcium-regulated parathyroid hormone secretion in normal
volunteers and patients with secondary hyperparathyroi-
dism. J Clin Endocrinol Metab 1993; 76: 1489-94.
30. Goodman WG, Gales B, Juppner H, Saluski IB. Calcium-
sensing by the parathyroids in severe secondary hyperpara-
thyroidism before parathyroidiectomy [abstract]. J Am Soc
Nephrol 1997; 8: 574A.
31. Pollak MR, Chou YH, Marx SJ, Steinmann B, Cole DE,
Brandi ML, et al. Familial hypocalciuric hypercalcemia and
neonatal severe hyperparathyroidism. Effects of mutant
gene dosage on phenotype. J Clin Invest 1994; 93: 1108-12.
32. Farnebo F, Enberg U, Grimelius L, Backdahl M, Schalling
M, Larsson C, et al. Tumor-specific decreased expression of
calcium sensing receptor messenger ribonucleic acid in
sporadic primary hyperparathyroidism. J Clin Endocrinol
Metabol 1997; 82: 3481-6.
33. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau
Y, Sarfati E, et al. Depressed expression of calcium receptor
in parathyroid gland tissue of patients with hyperparathy-
roidism. Kidney Int 1997; 51: 328-36.
34. Malmaeus J, Grimelius L, Johansson H, Akerstrom G,
Ljunghall S. Parathyroid pathology in hyperparathyroidism
secondary to chronic renal failure. Scand J Urol Nephrol
1984; 18: 157-66.
35. Gladziwa U, Ittel TH, Dakshinamurty KV, Schacht B, Riehl
J, Sieberth HG. Secondary hyperparathyroidism and sono-
graphic evaluation of parathyroid gland hyperplasia in dia-
lysis patients. Clin Nephrol 1992; 38: 162-6.
36. Yi H, Fukagawa M, Yamato H, Kumagai M, Watanabe T,
Kurokawa K. Prevention of enhanced parathyroid hormone
secretion, synthesis and hyperplasia by mild dietary phos-
phorus restriction in early chronic renal failure in rats:
possible direct role of phosphorus. Nephron 1995; 70: 242-8.
37. Szabo A, Merke J, Beier E, Mall G, Ritz E. 1,25(OH)2 vita-
min D3 inhibits parathyroid cell proliferation in
experimental uremia. Kidney Int 1989; 35: 1049-56.